Pharsight

Seebri patents expiration

SEEBRI's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6521260 NOVARTIS Carrier particles for use in dry powder inhalers
Jan, 2016

(8 years ago)

US6582678 NOVARTIS Carrier particles for use in dry powder inhalers
Apr, 2018

(6 years ago)

US6528678 NOVARTIS Phosgene-free process for preparing carbamates
Apr, 2018

(6 years ago)

US7229607 NOVARTIS Treatment of respiratory disease
Apr, 2021

(3 years ago)

US8029768 NOVARTIS Treatment of respiratory diseases
Apr, 2021

(3 years ago)

US7736670 NOVARTIS Method of making particles for use in a pharmaceutical composition
Jun, 2021

(2 years ago)

US9931304 NOVARTIS Method of making particles for use in a pharmaceutical composition
Jun, 2021

(2 years ago)

US8580306 NOVARTIS Particles for use in a pharmaceutical composition
Jun, 2021

(2 years ago)

US8303991 NOVARTIS Method of making particles for use in a pharmaceutical composition
Jun, 2021

(2 years ago)

US8048451 NOVARTIS Pharmaceutical compositions for inhalation
Jun, 2021

(2 years ago)

US8435567 NOVARTIS Pharmaceutical compositions of hydrophobic surface-modified active substance microparticles for inhalation
Jun, 2021

(2 years ago)

US8956661 NOVARTIS Method of making composite particles for use in pharmaceutical compositions and composite particles and compositions thereof
Jun, 2021

(2 years ago)

US9962338 NOVARTIS Method of making particles for use in a pharmaceutical composition
Jun, 2021

(2 years ago)

US8479730 NOVARTIS Inhaler device
Oct, 2028

(4 years from now)

US8182838 NOVARTIS Dry powder composition comprising co-jet milled particles for pulmonary inhalation
Oct, 2028

(4 years from now)

Seebri is owned by Novartis.

Seebri contains Glycopyrrolate.

Seebri has a total of 15 drug patents out of which 13 drug patents have expired.

Expired drug patents of Seebri are:

  • US6521260
  • US6582678
  • US6528678
  • US7229607
  • US8029768
  • US7736670
  • US9931304
  • US8580306
  • US8303991
  • US8048451
  • US8435567
  • US8956661
  • US9962338

Seebri was authorised for market use on 29 October, 2015.

Seebri is available in powder;inhalation dosage forms.

Seebri can be used as long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd).

The generics of Seebri are possible to be released after 20 October, 2028.

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 29, 2018

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using GLYCOPYRROLATE ingredient

Market Authorisation Date: 29 October, 2015

Treatment: Long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd)

Dosage: POWDER;INHALATION

More Information on Dosage

SEEBRI family patents

Family Patents